Private Company Edition: Playground’s third fund has $410m for tech, including biotech, Pivotal Life Sciences closed its second fund with $389m and Chugai will invest $200m through its new fund. Also, Tome launched with $213m, Sudo raised a $116m series B and Odyssey closed a $101m in series C.

French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.

The growth of markets within Asia is creating an enticing lure for medical device, pharmaceutical, and biomedical companies seeking to establish or enhance their presence in the region. Countries with large populations-and, in some cases, underserved medical needs for certain conditions-represent an opportunity to expand health care treatments. The government of Singapore is working hard to make sure foreign companies understand the island nation is very willing to offer that expertise and create an ideal location that could serve as a gateway to all of Asia.

Investors love to remind everyone that IPOs are financing events, not exiting events, using the mantra to put off Judgment Day for their investments. So how have device companies fared after the recent spate of IPOs?